Res 351 Week 4 Team Assignment Tracking

Ruiner (2017, PC)

By Real Soviet Bear / October 1, 2017


I give Ruiner a neutral score because the parts of it I enjoy are really good, but it's lacking in so many other aspects. The aesthetic and delivery of the game are fantastic. The setting is interesting, the "glitchy" effect is really good and in general it just oozes style. The game was definitely in need of a design pass, though. It has all the elements necessary to be great, but they needed to be re-arranged and reworked better.
   First off, the mid-fight resource management is really damn demanding. Your health and energy are in one corner of the screen, your ammo/durability are in the other, and your dash charges are center-bottom. Keeping track of all of these in a frantic fight is ridiculous, especially because the simple red UI blends with everything else in the game. There definitely should have been a better layout and clearer audio-visual cues so you know when you're hurting for something.

It's like a Bob Ross painting but with more sharp objects

   Skills have a lot of unnecessary fluff and you'll quickly learn what the best combo is. There are VERY FEW points where the game expects you to have a specific skill equipped, but other than that, you'll probably stick to shield + stun grenade + dash upgrades. It's along the lines of "Why would I have a wall I can place, when I can just have an insta-shield that negates damage regardless of where I am?" Or "Why would I have a frag grenade that deals damage when I can just disable any number of enemies?"
   This carries over to the weapons as well. Melee is always better, unless you are fighting a very specific boss and then you might want to switch to your ranged weapon. Melee stunlocks and deals more damage than almost any firearm in the game, especially in the first few hours.
   It also feels like the devs knew this? For example, melee interrupts enemies for the majority of the game, but then you get an enemy category that all of a sudden isn't interrupted by melee. That's fine, you can stun-grenade them. Well, now we have a "flaming" enemy type that is immune to the stun grenade specifically. Ok, that's fine, you can still ram them with your shield to stun them? It's a weird progression, but the strategy stays the same: disable, damage, disable, damage, avoid until you have enough energy again, repeat. This is enough to get you S+ rank on almost all fights.
   There are other weird things, like energy costs being relayed to you as numerical values, but your UI is actual icons? I assume each of the icons is 10 energy/health, but I never know whether I have enough or not to do my thing, so, combined with it being hard to track your stuff, I just never bother thinking about it.
   The enemy encounters could have been better laid out. Again, all the elements are there, but the waves are uninteresting. You'll have two melee dudes and two gun dudes. Ok, that's fine. Now you'll have a wave that's just suicide bombers. Now a wave that's just mines. Now a wave that's a draining device and one big dude. Why not throw in mines/suicide bombers in the midst of more varied waves? Then you can use them as tools against other enemies. There's very little target prioritization going on, because the actual battles aren't mixed up enough.
   Probably the two most frustrating moments for me were a boss battle with three health bars for no real reason (and you can just stun-lock him anyway) and that a very late fight has infinite spawns that the game literally teaches you up until then how to disable completely, and then the fight starts and it's like "nope, they're immune now, sorry".
   So, yeah, the game is very stylish, I don't regret playing it, but I think it needed one big design and balancing pass to actually capitalize on all its other strong points.
   For reference, I beat the game on Hard difficulty, since it was the "recommended" one.

1. ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr. 2002;26(1 Suppl):1SA–138SA.[PubMed]

2. Maroulis J, Kalfarentzos F. Complications of parenteral nutrition at the end of the century. Clin Nutr. 2000;19:295–304. doi: 10.1054/clnu.1999.0089. Available from: http://dx.doi.org/10.1054/clnu.1999.0089. [PubMed][Cross Ref]

3. Koretz RL, Lipman TO, Klein S American Gastroenterological Association. AGA technical review on parenteral nutrition. Gastroenterology. 2001;121(4):970–1001. doi: 10.1016/S0016-5085(01)92000-1. Available from: http://dx.doi.org/10.1016/S0016-5085(01)92000-1. [PubMed][Cross Ref]

4. Braunschweig CL, Levy P, Sheean PM, Wang X. Enteral compared with parenteral nutrition: a meta-analysis. Am J Clin Nutr. 2001;74(4):534–542.[PubMed]

5. Van den Berghe G. Insulin therapy for the critically ill patient. Clin Cornerstone. 2003;5(2):56–63. doi: 10.1016/S1098-3597(03)90018-4. Available from: http://dx.doi.org/10.1016/S1098-3597(03)90018-4. [PubMed][Cross Ref]

6. Marik PE, Pinsky M. Death by parenteral nutrition. Intensive Care Med. 2003;29(6):867–869. doi: 10.1007/s00134-003-1995-5. Available from: http://dx.doi.org/10.1007/s00134-003-1995-5. [PubMed][Cross Ref]

7. Anderson AD, Jain PK, MacFie J. Parenteral nutrition in the critically ill. Intensive Care Med. 2003;29(11):2103. doi: 10.1007/s00134-003-1996-4. Available from: http://dx.doi.org/10.1007/s00134-003-1996-4. [PubMed][Cross Ref]

8. Fürst P. Comment on "Death by parenteral nutrition" by Marik and Pinsky. Intensive Care Med. 2003;29(11):2102. doi: 10.1007/s00134-003-2023-5. Available from: http://dx.doi.org/10.1007/s00134-003-2023-5. [PubMed][Cross Ref]

9. Varga P, Griffiths R, Chiolero R, Nitenberg G, Leverve X, Pertkiewicz M, Roth E, Wernerman J, Pichard C, Preiser JC. Is parenteral nutrition guilty? Intensive Care Med. 2003;29(11):1861–1864. doi: 10.1007/s00134-003-2006-6. Available from: http://dx.doi.org/10.1007/s00134-003-2006-6. [PubMed][Cross Ref]

10. Alpers DH. Enteral feeding and gut atrophy. Curr Opin Clin Nutr Metab Care. 2002;5(6):679–683. doi: 10.1097/00075197-200211000-00011. Available from: http://dx.doi.org/10.1097/00075197-200211000-00011. [PubMed][Cross Ref]

11. Bistrian BR. Update on total parenteral nutrition. Am J Clin Nutr. 2001;74(2):153–154.[PubMed]

12. Jeejeebhoy KN. Total parenteral nutrition: potion or poison? Am J Clin Nutr. 2001;74(2):160–163.[PubMed]

13. Richards DM, Deeks JJ, Sheldon TA, Shaffer JL. Home parenteral nutrition: a systematic review. Health Technol Assess. 1997;1(1):i–iii, 1.[PubMed]

14. Klein S. A primer of nutritional support for gastroenterologists. Gastroenterology. 2002;122(6):1677–1687. doi: 10.1053/gast.2002.33574. Available from: http://dx.doi.org/10.1053/gast.2002.33574. [PubMed][Cross Ref]

15. Buchman AL, Moukarzel AA, Bhuta S, Belle M, Ament ME, Eckhert CD, Hollander D, Gornbein J, Kopple JD, Vijayaroghavan SR. Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. JPEN J Parenter Enteral Nutr. 1995;19(6):453–460. doi: 10.1177/0148607195019006453. Available from: http://dx.doi.org/10.1177/0148607195019006453. [PubMed][Cross Ref]

16. Guedon C, Schmitz J, Lerebours E, Metayer J, Audran E, Hemet J, Colin R. Decreased brush border hydrolase activities without gross morphologic changes in human intestinal mucosa after prolonged total parenteral nutrition of adults. Gastroenterology. 1986;90(2):373–378.[PubMed]

17. Pironi L, Paganelli GM, Miglioli M, Biasco G, Santucci R, Ruggeri E, Di Febo G, Barbara L. Morphologic and cytoproliferative patterns of duodenal mucosa in two patients after long-term total parenteral nutrition: changes with oral refeeding and relation to intestinal resection. JPEN J Parenter Enteral Nutr. 1994;18(4):351–354. doi: 10.1177/0148607194018004351. Available from: http://dx.doi.org/10.1177/0148607194018004351. [PubMed][Cross Ref]

18. Sedman PC, MacFie J, Palmer MD, Mitchell CJ, Sagar PM. Preoperative total parenteral nutrition is not associated with mucosal atrophy or bacterial translocation in humans. Br J Surg. 1995;82(12):1663–1667. doi: 10.1002/bjs.1800821226. Available from: http://dx.doi.org/10.1002/bjs.1800821226. [PubMed][Cross Ref]

19. van der Hulst RR, van Kreel BK, von Meyenfeldt MF, Brummer RJ, Arends JW, Deutz NE, Soeters PB. Glutamine and the preservation of gut integrity. Lancet. 1993;341(8857):1363–1365. doi: 10.1016/0140-6736(93)90939-E. Available from: http://dx.doi.org/10.1016/0140-6736(93)90939-E. [PubMed][Cross Ref]

20. van der Hulst RR, von Meyenfeldt MF, Tiebosch A, Buurman WA, Soeters PB. Glutamine and intestinal immune cells in humans. JPEN J Parenter Enteral Nutr. 1997;21(6):310–315. doi: 10.1177/0148607197021006310. Available from: http://dx.doi.org/10.1177/0148607197021006310. [PubMed][Cross Ref]

21. van der Hulst RR, von Meyenfeldt MF, Deutz NE, Stockbrügger RW, Soeters PB. The effect of glutamine administration on intestinal glutamine content. J Surg Res. 1996;61(1):30–34. doi: 10.1006/jsre.1996.0076. Available from: http://dx.doi.org/10.1006/jsre.1996.0076. [PubMed][Cross Ref]

22. Ahlman B, Ljungqvist O, Persson B, Bindslev L, Wernerman J. Intestinal amino acid content in critically ill patients. JPEN J Parenter Enteral Nutr. 1995;19(4):272–278. doi: 10.1177/0148607195019004272. Available from: http://dx.doi.org/10.1177/0148607195019004272. [PubMed][Cross Ref]

23. Hadfield RJ, Sinclair DG, Houldsworth PE, Evans TW. Effects of enteral and parenteral nutrition on gut mucosal permeability in the critically ill. Am J Respir Crit Care Med. 1995;152(5 Pt 1):1545–1548.[PubMed]

24. Safe Practices for Parenteral Nutrition Formulations. National Advisory Group on Standards and Practice Guidelines for Parenteral Nutrition. JPEN J Parenter Enteral Nutr. 1998;22(2):49–66. doi: 10.1177/014860719802200249. Available from: http://dx.doi.org/10.1177/014860719802200249. [PubMed][Cross Ref]

25. Llop J, Sabin P, Garau M, Burgos R, Pérez M, Massó J, Cardona D, Sánchez Segura JM, Garriga R, Redondo S, Sagalés M, Ferrer D, Pons M, Vuelta M, Fàbregas X, Vitales M, Casasín T, Martínez J, Morató L, Soler M Hospital Pharmacy Artificial Nutrition Group of Catalonia. The importance of clinical factors in parenteral nutrition-associated hypertriglyceridemia. Clin Nutr. 2003;22(6):577–583. doi: 10.1016/S0261-5614(03)00082-7. Available from: http://dx.doi.org/10.1016/S0261-5614(03)00082-7. [PubMed][Cross Ref]

26. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA. 2003;290(15):2041–2047. doi: 10.1001/jama.290.15.2041. Available from: http://dx.doi.org/10.1001/jama.290.15.2041. [PubMed][Cross Ref]

27. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997;314(7093):1512–1515.[PMC free article][PubMed]

28. Meier JJ, Deifuss S, Gallwitz B, Klamann A, Schmiegel W, Nauck MA. Einfluss einer eingeschränkten Glukosetoleranz auf das Langzeitüberleben nach akutem Myokardinfarkt The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA) [Influence of impaired glucose tolerance on long-term survival after acute myocardial infarction]. Dtsch Med Wochenschr. 2002;127(21):1123–1129. doi: 10.1055/s-2002-31529. (Ger). Available from: http://dx.doi.org/10.1055/s-2002-31529. [PubMed][Cross Ref]

29. Norhammar AM, Rydén L, Malmberg K. Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care. 1999;22(11):1827–1831. doi: 10.2337/diacare.22.11.1827. Available from: http://dx.doi.org/10.2337/diacare.22.11.1827. [PubMed][Cross Ref]

30. Parsons MW, Barber PA, Desmond PM, Baird TA, Darby DG, Byrnes G, Tress BM, Davis SM. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol. 2002;52(1):20–28. doi: 10.1002/ana.10241. Available from: http://dx.doi.org/10.1002/ana.10241. [PubMed][Cross Ref]

31. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87(3):978–982. doi: 10.1210/jc.87.3.978. Available from: http://dx.doi.org/10.1210/jc.87.3.978. [PubMed][Cross Ref]

32. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345(19):1359–1367. doi: 10.1056/NEJMoa011300. Available from: http://dx.doi.org/10.1056/NEJMoa011300. [PubMed][Cross Ref]

33. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ. 1997;314(7090):1303–1306.[PMC free article][PubMed]

34. Zindrou D, Taylor KM, Bagger JP. Admission plasma glucose: an independent risk factor in nondiabetic women after coronary artery bypass grafting. Diabetes Care. 2001;24(9):1634–1639. doi: 10.2337/diacare.24.9.1634.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *